Selinisol for the treatment of acute myeloid leukemia

Selinexor is an antineoplastic agent approved by the FDA in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In combination with dexamethasone, it is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma(MM) who have received at least four prior therapies and whose disease is responsive to at least two proteasome inhibitors, at least two immunomodulators, and an antiCD38 monoclonal antibody. For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including those caused by follicular lymphoma, after at least 2 systemic therapies.

Selinexor （selinexor) is still being explored in the treatment of acute myeloid leukemia. Currently, FDA has not approved selinexor for the treatment of acute myeloid leukemia. Acute myeloid leukemia (AML) is a malignant clonal disease derived from hematopoietic stem cells. It mostly occurs in the elderly. The incidence rate increases with age. Elderly patients with AML have poor tolerance to treatment and poor prognosis. Hematopoietic stem cell transplantation is still the only possible cure for AML.

In nonclinical studies, selinesol reversibly inhibits the nuclear export of tumor suppressor protein(tsp), growth regulator, and oncogenic proteinmRNAs by blocking exportin 1 (XPO1). Inhibition of XPO1 by selinesol leads to the accumulation of tsp in the nucleus and several oncoproteins(< /span>For example, the reduction of c-myc and cyclin D1), cell cycle arrest and apoptosis of cancer cells. Selinisol is effective in treating multiple myeloma and diffuse large Bcell lymphoma. The cost of each box of generic drugs is about three to four thousand yuan. For details, please consult overseas pharmaceutical institutions. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.